Context Therapeutics Inc. - 8-K Filing
Context Therapeutics Inc. amended its License Agreement with BioAtla, Inc., paying $4.5 million on May 14, 2026, and an additional $2.0 million by August 1, 2026. The amendment made the license for CT-202 royalty-free, fully paid-up, irrevocable, and non-terminable while eliminating future milestone payments or royalties to BioAtla. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Exhibits)
Tickers: $CNTX